These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19655394)

  • 1. Retroviral vector production under serum deprivation: The role of lipids.
    Rodrigues AF; Carmo M; Alves PM; Coroadinha AS
    Biotechnol Bioeng; 2009 Dec; 104(6):1171-81. PubMed ID: 19655394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptation of retrovirus producer cells to serum deprivation: Implications in lipid biosynthesis and vector production.
    Rodrigues AF; Amaral AI; Veríssimo V; Alves PM; Coroadinha AS
    Biotechnol Bioeng; 2012 May; 109(5):1269-79. PubMed ID: 22179842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of medium sugar source on the production of retroviral vectors for gene therapy.
    Coroadinha AS; Ribeiro J; Roldão A; Cruz PE; Alves PM; Merten OW; Carrondo MJ
    Biotechnol Bioeng; 2006 May; 94(1):24-36. PubMed ID: 16514678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability.
    Coroadinha AS; Silva AC; Pires E; Coelho A; Alves PM; Carrondo MJ
    Biotechnol Bioeng; 2006 Jun; 94(2):322-9. PubMed ID: 16528756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Closed hollow-fiber bioreactor: a new approach to retroviral vector production.
    Pan D; Whitley CB
    J Gene Med; 1999; 1(6):433-40. PubMed ID: 10753069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor.
    Ghani K; Garnier A; Coelho H; Transfiguracion J; Trudel P; Kamen A
    Biotechnol Bioeng; 2006 Nov; 95(4):653-60. PubMed ID: 16947907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different bioreactor systems for the production of high titer retroviral vectors.
    Merten OW; Cruz PE; Rochette C; Geny-Fiamma C; Bouquet C; Gonçalves D; Danos O; Carrondo MJ
    Biotechnol Prog; 2001; 17(2):326-35. PubMed ID: 11312711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrovirus producer cell line metabolism: implications on viral productivity.
    Coroadinha AS; Alves PM; Santos SS; Cruz PE; Merten OW; Carrondo MJ
    Appl Microbiol Biotechnol; 2006 Oct; 72(6):1125-35. PubMed ID: 16598449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of retroviral vector generation for clinical application.
    Schilz AJ; Kühlcke K; Fauser AA; Eckert HG
    J Gene Med; 2001; 3(5):427-36. PubMed ID: 11601756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18.
    Gerin PA; Searle PF; Al-Rubeai M
    Biotechnol Prog; 1999; 15(5):941-8. PubMed ID: 10514266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations.
    Kaptein LC; Greijer AE; Valerio D; van Beusechem VW
    Gene Ther; 1997 Feb; 4(2):172-6. PubMed ID: 9081708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line.
    McTaggart S; Al-Rubeai M
    Biotechnol Prog; 2000; 16(5):859-65. PubMed ID: 11027182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A heterologous system for assembly of retroviral gene vectors: intracellular budding in yeast?
    Tolmachov O
    Med Hypotheses; 2006; 67(4):807-9. PubMed ID: 16759811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange.
    Coroadinha AS; Schucht R; Gama-Norton L; Wirth D; Hauser H; Carrondo MJ
    J Biotechnol; 2006 Jul; 124(2):457-68. PubMed ID: 16529836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer.
    Sheridan PL; Bodner M; Lynn A; Phuong TK; DePolo NJ; de la Vega DJ; O'Dea J; Nguyen K; McCormack JE; Driver DA; Townsend K; Ibañez CE; Sajjadi NC; Greengard JS; Moore MD; Respess J; Chang SM; Dubensky TW; Jolly DJ; Sauter SL
    Mol Ther; 2000 Sep; 2(3):262-75. PubMed ID: 10985957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State-of-the-art of the production of retroviral vectors.
    Merten OW
    J Gene Med; 2004 Feb; 6 Suppl 1():S105-24. PubMed ID: 14978755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
    Ghani K; Cottin S; Kamen A; Caruso M
    Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors.
    Farson D; Harding TC; Tao L; Liu J; Powell S; Vimal V; Yendluri S; Koprivnikar K; Ho K; Twitty C; Husak P; Lin A; Snyder RO; Donahue BA
    J Gene Med; 2004 Dec; 6(12):1369-81. PubMed ID: 15538729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.
    Persons DA; Mehaffey MG; Kaleko M; Nienhuis AW; Vanin EF
    Blood Cells Mol Dis; 1998 Jun; 24(2):167-82. PubMed ID: 9642098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.
    Schucht R; Coroadinha AS; Zanta-Boussif MA; Verhoeyen E; Carrondo MJ; Hauser H; Wirth D
    Mol Ther; 2006 Aug; 14(2):285-92. PubMed ID: 16697259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.